Tilray AI Stock Analysis
Want to see TLRY full AI Analyst Report?
Tilray (TLRY) AI Stock Analysis
Tilray
(NASDAQ:TLRY)
The score is held back primarily by weak financial performance (continued losses and negative free cash flow) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a more constructive earnings-call backdrop (record revenue/margin expansion and reaffirmed EBITDA guidance) and modestly positive balance-sheet actions, while valuation remains difficult to support given ongoing losses and no dividend.
Tilray (TLRY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $291.88M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.19M
- Price to Earnings (P/E)
- -1.9
- Beta (1Y)
- 1.17
- Revenue Growth
- 15.93%
- EPS Growth
- 93.85%
- Country
- US
- Employees
- 3,595
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Tilray Business Overview & Revenue Model
Company Description
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, t...
How the Company Makes Money
Tilray makes money primarily by selling branded and bulk products across its operating segments, with revenue recognized largely from the shipment/delivery of products to customers through a mix of direct sales and distributor/retail channels. Key re...
Tilray Earnings Call Summary
The call was predominantly positive. Tilray reported record revenue and gross profit, expanding consolidated and cannabis margins, strong international cannabis and BrewDog growth, U.S. craft beer brand momentum, debt reduction, and reaffirmed fiscal 2027 adjusted EBITDA guidance. These strengths were partly offset by a $40 million net loss, lower adjusted EBITDA, total cannabis revenue contraction, international price compression, Canadian adult-use headwinds, fuel costs, higher investment costs, and continued regulatory and market uncertainty.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Tilray is maintaining and reaffirming its fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million; it expects its Portugal facility to deliver more than 40 metric tons of flower at full capacity in our fiscal year 2027, expects a larger impact from new cultivars late in Q2 and beyond, is focused on doubling Lyphe's patient base, expects BrewDog's budget for this year is profitability and some good profitability coming from BrewDog, and expects the Carlsberg partnership, beginning January 1, 2027, to deliver immediate scale, revenue contribution when it begins.
Tilray Financial Statement Overview
Summary
Financial health is mixed. Revenue is roughly flat (~-2.7% TTM) with continued net losses (net margin ~-12.9%) and negative operating/free cash flow (OCF ~-$88M, FCF ~-$116M). The balance sheet is comparatively supportive with moderate leverage (debt-to-equity ~0.25), but ongoing cash burn and lack of consistent profitability keep the score low.
Income Statement
32NegativeBalance Sheet
63PositiveCash Flow
28Negative| Breakdown | TTM | May 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 963.10M | 915.45M | 821.31M | 788.94M | 627.12M | 628.37M |
| Gross Profit | 274.29M | 260.44M | 240.57M | 223.35M | 146.96M | 116.82M |
| EBITDA | -18.52M | 9.45M | -2.13B | -72.84M | -1.27B | -246.40M |
| Net Income | -164.22M | -122.57M | -2.19B | -244.98M | -1.45B | -476.80M |
Balance Sheet | ||||||
| Total Assets | 2.33B | 2.33B | 2.07B | 4.22B | 4.31B | 5.45B |
| Cash, Cash Equivalents and Short-Term Investments | 218.01M | 231.27M | 251.24M | 253.69M | 439.31M | 415.91M |
| Total Debt | 371.93M | 398.40M | 322.16M | 377.17M | 578.00M | 623.81M |
| Total Liabilities | 721.28M | 733.14M | 614.55M | 868.73M | 1.05B | 1.01B |
| Stockholders Equity | 1.62B | 1.61B | 1.48B | 3.35B | 3.25B | 4.40B |
Cash Flow | ||||||
| Free Cash Flow | -119.00M | -102.13M | -127.52M | -60.15M | -12.89M | -211.33M |
| Operating Cash Flow | -84.49M | -69.14M | -94.60M | -30.91M | 7.91M | -177.26M |
| Investing Cash Flow | -89.73M | -55.80M | -46.72M | 128.35M | -285.11M | -21.53M |
| Financing Cash Flow | 125.38M | 130.99M | 133.51M | -75.19M | 70.16M | 128.20M |
Tilray Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLRY, the sentiment is Negative. The current price of 2.61 is below the 20-day moving average (MA) of 2.82, below the 50-day MA of 3.48, and below the 200-day MA of 5.22, indicating a bearish trend. The MACD of -0.22 indicates Negative momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 42.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TLRY.
Tilray Risk Analysis
Tilray disclosed 61 risk factors in its most recent earnings report. Tilray reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksTilray Peers Comparison
Overall Rating
TRLV65Neutral
INM50Neutral- TLRY49Neutral
YCBD43Neutral
IMCC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TRLV | 65Neutral | $2.14B | -4.87 | -46.07% | ― | -9.09% | -230.91% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INM | 50Neutral | $6.70M | -0.50 | -303.50% | ― | -82.91% | 55.05% |
| TLRY | 49Neutral | $391.64M | -1.86 | -10.30% | ― | 15.93% | 93.85% |
| YCBD | 43Neutral | $4.30M | -1.29 | -34.25% | ― | 10.01% | 95.01% |
| IMCC | 37Underperform | $1.01M | -0.02 | 841.81% | ― | -11.91% | -285.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TLRY | Tilray | 2.61 | -8.69 | -76.90% | |
| INM | Inmed Pharmaceuticals Inc. | 15.61 | -2.49 | -13.76% | |
| YCBD | Cbdmd INc | 0.40 | -0.34 | -46.62% | |
| TRLV | Trulieve Cannabis | 11.23 | 5.08 | 82.60% | |
| IMCC | Im Cannabis Corp | 0.57 | -38.72 | -98.54% | |
| AKAN | Akanda Corp | 0.73 | -28.29 | -97.47% |
Tilray Corporate Events
Tilray Reduces Debt Through Private Equity Exchange
NeutralBetween August 31, 2026 and September 8, 2026, Tilray Brands, Inc. executed private debt-for-equity exchange transactions with unrelated holders of its 5.20% Convertible Senior Notes due June 15, 2027, swapping $12 million in note principal for 2,841...
Tilray Reduces Convertible Debt Through Private Equity Exchange
PositiveOn August 4, 2026, Tilray Brands, Inc. executed private debt-for-equity exchange transactions with unrelated parties, issuing 1,377,334 shares of common stock in exchange for $6 million in principal amount of its 5.20% Convertible Senior Notes due Ju...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026